Companies · Other Health Care

Gynesonics, Inc

REDWOOD CITY · Other Health Care

Diligence memoA one-page analyst read on Gynesonics, Inc — recommendation, valuation, rhythm, risks.
$299.1M
Total raised · real
12
Rounds
1.9×
Latest step-up
Top 2%
Sector rank · raised
Series C
Latest stage · inferred · Thu Apr 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Gynesonics, Inc looks over-valued against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 1.58× the median modeled value of Series C Other Health Care companies in 2022–2024 (47 peers) — value vs value, same stage and era.
At-risk
  • Last raise 3.2 yr ago; this sector typically re-raises about every 14 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

Gynesonics, Inc is one of 5376 Other Health Care companies tracked from REDWOOD CITY. By capital raised it ranks among the largest (ahead of 99% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
13
Investors (latest)
2023-04-06
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$500M$1.0B$1.5B$2.0BSeed · 2009-11-04 Raised $1.5M (real) Modeled valuation $37M (est)Seed2009Series B · 2010-05-05 Raised $15M (real) Modeled valuation $335M (est)Series B2010Series B · 2010-05-05 Raised $16M (real) Modeled valuation $345M (est)Series B2010Series B · 2010-10-15 Raised $455K (real) Modeled valuation $10M (est)Series B2010Series B · 2012-02-08 Raised $5.0M (real) Modeled valuation $111M (est)Series B2012Series B · 2012-12-05 Raised $900K (real) Modeled valuation $20M (est)Series B2012Series B · 2013-01-16 Raised $900K (real) Modeled valuation $20M (est)Series B2013Series B · 2013-02-08 Raised $22M (real) Modeled valuation $491M (est)Series B2013Series B · 2013-02-08 Raised $28M (real) Modeled valuation $630M (est)Series B2013Series B · 2015-04-09 Raised $3.0M (real) Modeled valuation $66M (est)Series B2015Series C · 2015-07-14 Raised $43M (real) Modeled valuation $986M (est)Series C2015Series C · 2018-12-18 Raised $75M (real) Modeled valuation $1.7B (est)Series C2018Series C · 2021-12-15 Raised $33M (real) Modeled valuation $511M (est)Series C2021Series C · 2023-04-06 Raised $49M (real) Modeled valuation $556M (est)Series C2023Series C · 2023-04-06 Raised $92M (real) Modeled valuation $1.0B (est)Series C2023Cumulative $386M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$1.5M · 2009
Series B$15.1M · 2010no Series A on file
Series B extension$15.6M · 2010
Series B extension$455K · 2010
Series B extension$5.0M · 2012
Series B extension$900K · 2012
Series B extension$900K · 2013
Series B extension$22.2M · 2013
Series B extension$28.4M · 2013
Series B extension$3.0M · 2015
Series C$43.1M · 2015
Series C extension$75.5M · 2018
Series C extension$32.5M · 2021
Series C extension$49.5M · 2023
Series C extension$92.2M · 2023

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 60%.

Modeled valuation trajectory
$1.0B
Base estimate est.
$335.1M
Conservative case
$1.9B
Upside case
$614.6M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Seed · modeled $37.2M · 2009-11-042009Series B · modeled $335.0M · 2010-05-05Series B · modeled $345.4M · 2010-05-05Series B · modeled $10.1M · 2010-10-15Series B · modeled $110.8M · 2012-02-08Series B · modeled $19.9M · 2012-12-05Series B · modeled $19.9M · 2013-01-16Series B · modeled $491.0M · 2013-02-08Series B · modeled $630.3M · 2013-02-08Series B · modeled $66.5M · 2015-04-09Series C · modeled $986.4M · 2015-07-14Series C · modeled $1.7B · 2018-12-18Series C · modeled $510.8M · 2021-12-15Series C · modeled $556.0M · 2023-04-06Series C · modeled $1.0B · 2023-04-062023
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
73%
Survival probability
55% low · 85% high
1.29×/yr
Annual markup
1.48×/yr upside case
3.2 yr
Elapsed time used
3.2 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
12 mo
Avg between rounds
$22.3M/yr
Capital velocity
16.7 yr
On record since
2009
First round
15
Rounds on file
How it compares to the market

Benchmarked against 5376 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 123× above median
This company$299.1M
Sector median$2.4M
Latest round — vs other Series C rounds in sector (real $, this stage) 2.0× above median
This company$92.2M
Sector median$45.9M
Modeled value — vs sector median (estimate, all stages) 47× above median
This company$1.0B
Sector median$22.1M

Raised more than 99% of sector peers (real $). Modeled value above 97% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #5 of 47.

This companyCohort peer
$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Gravie, Inc. · Series C Raised $160.7M · modeled $1.3B (est)EmpowerMe Holdings, LLC · Series C Raised $96.6M · modeled $1.3B (est)Color Holdings, L.P. · Series C Raised $90.9M · modeled $1.1B (est)RSR Senior Residences, LLC · Series C Raised $73.7M · modeled $1.1B (est)Hello Heart Inc. · Series C Raised $127.0M · modeled $1.0B (est)Beta Bionics, Inc · Series C Raised $277.5M · modeled $1.0B (est)BioDerm Holdings, LP · Series C Raised $130.9M · modeled $1.0B (est)Kindbody, Inc. · Series C Raised $95.6M · modeled $874.4M (est)Drconsulta Ltd. · Series C Raised $140.1M · modeled $836.7M (est)Fountain Life, LLC · Series C Raised $103.9M · modeled $827.7M (est)TherapyMatch, Inc. · Series C Raised $100.0M · modeled $808.6M (est)Gynesonics, Inc (this company) Raised $299.1M · modeled $1.0B (est)Gynesonics, Inc
CompanyStageRaised · realValue · estvs peer med.
Gravie, Inc.Series C$160.7M$1.3B2.04×
EmpowerMe Holdings, LLCSeries C$96.6M$1.3B1.92×
Color Holdings, L.P.Series C$90.9M$1.1B1.75×
RSR Senior Residences, LLCSeries C$73.7M$1.1B1.71×
Gynesonics, Inc this companySeries C$299.1M$1.0B1.58×
Hello Heart Inc.Series C$127.0M$1.0B1.54×
Beta Bionics, IncSeries C$277.5M$1.0B1.54×
BioDerm Holdings, LPSeries C$130.9M$1.0B1.53×
Kindbody, Inc.Series C$95.6M$874.4M1.33×
Drconsulta Ltd.Series C$140.1M$836.7M1.28×
Fountain Life, LLCSeries C$103.9M$827.7M1.26×
TherapyMatch, Inc.Series C$100.0M$808.6M1.23×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$1.5M2009-11-04$7.5M$37.2M85%
Series B$15.1M2010-05-05$84.0M$335.0M85%
Series B$15.6M2010-05-05$86.6M$345.4M85%
Series B$455K2010-10-15$2.5M$10.1M85%
Series B$5.0M2012-02-08$27.8M$110.8M85%
Series B$900K2012-12-05$5.0M$19.9M85%
Series B$900K2013-01-16$5.0M$19.9M85%
Series B$22.2M2013-02-08$123.1M$491.0M85%
Series B$28.4M2013-02-08$158.0M$630.3M85%
Series B$3.0M2015-04-09$16.7M$66.5M85%
Series C$43.1M2015-07-14$287.6M$986.4M85%
Series C$75.5M2018-12-18$503.1M$1.7B90%
Series C$32.5M2021-12-15$216.7M$510.8M90%
Series C$49.5M2023-04-06$330.0M$556.0M90%
Series C$92.2M2023-04-06$614.6M$1.0B90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$1.5M2009-11-04
    • First recorded raise — entered as Seed.
    • 7 investors on this round.
  2. Series B$15.1M2010-05-05
    • Came back fast: 6 mo vs the ~14 mo sector norm.
    • Round 10.1× larger than the prior — scaling up.
    • 7 investors on this round.
  3. Series B$15.6M2010-05-05
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 7 investors on this round.
  4. Series B$455K2010-10-15
    • Came back fast: 5 mo vs the ~14 mo sector norm.
    • Round 34.3× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  5. Series B$5.0M2012-02-08
    • Raised 16 mo later, in step with the ~14 mo sector norm.
    • Round 11.0× larger than the prior — scaling up.
    • 8 investors on this round.
  6. Series B$900K2012-12-05
    • Raised 10 mo later, in step with the ~14 mo sector norm.
    • Round 5.6× smaller than the prior — bridge or down round.
    • 9 investors on this round.
  7. Series B$900K2013-01-16
    • Came back fast: 1 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 9 investors on this round.
  8. Series B$22.2M2013-02-08
    • Came back fast: 1 mo vs the ~14 mo sector norm.
    • Round 24.6× larger than the prior — scaling up.
    • 16 investors on this round.
  9. Series B$28.4M2013-02-08
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • Switched to Rule 506(b) (was Rule 06).
    • 16 investors on this round.
  10. Series B$3.0M2015-04-09
    • Raised again after 26 mo — slower than the ~14 mo sector norm.
    • Round 9.5× smaller than the prior — bridge or down round.
    • 12 investors on this round.
  11. Series C$43.1M2015-07-14
    • Came back fast: 3 mo vs the ~14 mo sector norm.
    • Round 14.4× larger than the prior — scaling up.
    • 16 investors on this round.
  12. Series C$75.5M2018-12-18
    • Raised again after 41 mo — slower than the ~14 mo sector norm.
    • Round 1.7× larger than the prior — scaling up.
    • 21 investors on this round.
  13. Series C$32.5M2021-12-15
    • Raised again after 36 mo — slower than the ~14 mo sector norm.
    • Round 2.3× smaller than the prior — bridge or down round.
    • 18 investors on this round.
  14. Series C$49.5M2023-04-06
    • Raised 16 mo later, in step with the ~14 mo sector norm.
    • Round 1.5× larger than the prior — scaling up.
    • 7 investors on this round.
  15. Series C$92.2M2023-04-06
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.9× larger than the prior — scaling up.
    • 13 investors on this round.
Intelligence
2024 ~Q1
Modeled next raise · ~12mo cadence
$171.7M
Modeled next size est.range $111.6M$274.7M
1.9×
Last step-up
$22.3M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Robert Brown21 other2021-12
JEFFREY SCHWARTZ8 other2021-12
Joyce Erony7 other2021-12
David Neustaedter6 other2021-12
Jonathan MacQuitty6 other2010-10
Tom Rodgers3 other2009-11
Chandra Leo2 other2021-12
Christopher M Owens2 other2013-02
Darrin Uecker2 other2009-11
Doug Fisher2 other2012-02
Hugo Harrod2 other2023-04
Karen Talmadge2 other2009-11
Mike Carusi2 other2012-12
Alexander Schmitz1 other2023-04
Chandra P. Leo1 other2013-02
Christopher Owens1 other2015-04
David M. Neustaedter1 other2018-12
Jeffrey M. Schwartz1 other2018-12
Ken Haas1 other2009-11
Ken M. Haas1 other2013-02
Louis Baldino1 other2023-04
Robert M. O'Holla1 other2018-12
Susan Stimson1 other2021-12
Chandra M. Leo2018-12
Registry & provenance

Gynesonics, Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1341675
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Rapid Micro Biosystems, Inc.Other Health CareSeries C$134.6M$1.4Bnetwork2 shared operators · same sector · same stage
R3 Vascular Inc.Other Health CareSeries C$75.2M$620.6Mnetwork2 shared operators · same sector · same stage
Relievant MedSystems IncOther Health CareSeries C$200.1M$522.9Mnetwork1 shared operator · same sector · same stage
Nuvaira, Inc.Other Health CareSeries C$177.8M$191.7Mnetwork1 shared operator · same sector · same stage
Endogastric Solutions IncOther Health CareSeries C$177.3M$557.2Mnetwork1 shared operator · same sector · same stage
Bigfoot Biomedical, Inc.Other Health CareSeries C$144.1M$1.3Bnetwork1 shared operator · same sector · same stage
IDev Technologies IncOther Health CareSeries B$44.2M$18.4Mnetwork2 shared operators · same sector
Miach Orthopaedics Inc.Other Health CareSeries C$67.8M$44.0Mnetwork1 shared operator · same sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Gynion, LLCOther Health CarePre-Seed$12.0M87%
Endomedix, IncOther Health CareSeed$29.4M85%
Glooko, Inc.Other Health CareSeries D+$1.2B84%
Zynex IncOther Health CareSeed$37.2M84%
Glyscend, Inc.Other Health CareSeries A$96.9M83%
Gravie, Inc.Other Health CareSeries C$1.3B83%
BioCeryx Inc.Other Health CareSeries A$100.9M83%
General Fluidics CorpOther Health CareSeries B$119.3M83%
Frequently asked
How much funding has Gynesonics, Inc raised?
Gynesonics, Inc has raised approximately $299.1M in disclosed capital across 12 recorded financing rounds, aggregated from public filings.
What is Gynesonics, Inc's estimated valuation?
Provath's modeled valuation for Gynesonics, Inc is approximately $1.0B (modeled range $335.1M–$1.9B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Gynesonics, Inc at?
Gynesonics, Inc's latest modeled financing stage is Series C. Its most recent recorded round closed around Thu Apr 06.
What does Gynesonics, Inc do and where is it based?
Gynesonics, Inc operates in the Other Health Care sector, based in REDWOOD CITY.
Explore related

See where Gynesonics, Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Gynesonics, Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.